Bioequivalence Study of Calcifediol Monohydrate 0.266 mg Soft Capsules in Healthy Subjects Under Fasting Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Calcifediol monohydrate 0.266 mg soft capsules in healthy participants under fasting conditions. This assessment is clinically relevant as it determines whether the test formulation of Calcifediol monohydrate is equivalent in its pharmacokinetic properties to a reference formulation, ensuring consistent therapeutic effects and safety profiles. No secondary objectives are specified for this study.

The clinical trial involves a study population that includes both **female** and **male** participants. The age range of the participants is categorized as **adults**. The trial population selection process and specific lifestyle considerations, such as diet or physical activity, have not been detailed. The study does not focus on any particular medical condition, as indicated by the absence of a specified medical condition. The sponsor has not provided information regarding the total number of participants involved in the trial. Additionally, the trial includes a **vulnerable population**, although further details on this aspect are not specified. Key inclusion or exclusion criteria have not been disclosed.

The clinical trial is designed to evaluate the **bioequivalence** of Calcifediol monohydrate 0.266 mg soft capsules in healthy participants under fasting conditions. This study is a Phase 2 trial, which will be conducted as a randomized, double-blind, controlled trial. The estimated recruitment start date is December 12, 2024, with an anticipated end date of May 22, 2025. The trial does not involve any specific medical condition, as it is focused on healthy participants.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive the investigational product or a control under fasting conditions. The trial will include multiple follow-up visits to monitor safety, tolerability, and pharmacokinetic parameters. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to ensure participant safety and collect any remaining data.

The expected length of participant involvement will span the duration of the trial, from the initial screening visit through to the end-of-study visit. Conditions that may lead to early termination from the study include non-compliance with study procedures, adverse events that compromise participant safety, or withdrawal of consent. The trial is structured to ensure rigorous adherence to scientific and ethical standards, with all procedures conducted in accordance with regulatory guidelines.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on December 12, 2024, with an estimated completion date of May 22, 2025. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the available information. The trial's focus on efficacy will be aligned with the objectives typical of a Phase 2 study, which generally aims to evaluate the effectiveness of the intervention in a controlled setting.